July 10, 2008 (FinancialWire) Biopharmaceutical company Altus Pharmaceuticals Inc. (NASDAQ: ALTU) has signed a long-term deal to buy a growth hormone ingredient from a unit of Novartis AG (NYSE: NVS). Financial details of the deal were not disclosed. Under the deal, Novartis’ Sandoz GmbH will continue supplying human growth hormone for Altus’ ALTU-238 program.
